JournalofPerinatology(2017)00,1–6
©2017NatureAmerica,Inc.,partofSpringerNature.Allrightsreserved0743-8346/17
www.nature.com/jp
ORIGINAL ARTICLE
Association of unit-wide oxygen saturation target on incidence
of pulmonary hypertension in very low birthweight premature
infants
UKanaan1,2,3, BSrivatsa3,4,JHuckaby2 and MKelleman1
OBJECTIVE:Assesstheeffectofincreasingpulseoximetrytargetsonincidenceofpulmonaryhypertensioninverylowbirthweight
premature infants.
STUDY DESIGN:Retrospective cohort study comparing pulmonary hypertensionincidence amongthree cohortsof premature
infantsexposedtovaryingoxygensaturationtargets(Cohort1:n=459,1May2009to30April2011,85–94%;Cohort2:n=474,1
May2011to31May2013,88–94%;Cohort3:n=387,1June2013to31May2015,90–95%).Subjectshadbirthweight o1500g
andgestational age23–32weeks. Chi-square, Kruskall–Wallisand Anderson–Darling tests wereused,aswell asmultivariable
logisticregression.
RESULTS:Incidence ofpulmonary hypertensiondeclinedwith higheroxygen saturationtargets (19.0% Cohort 1, 7.9%Cohort 2,
9.6%Cohort 3, Po0.001). Other parameters werelargelynot different betweencohorts though ratesof chorioamnionitis and
prenatalsteroidsincreasedandoxygenuse,inhalednitricoxideuse,necrotizingenterocolitisandpatentductusarteriosusligation
decreased overtime.
CONCLUSION:Higheroxygensaturationtargetsforverylow-birthweightprematureinfantswereassociatedwithreducedratesof
pulmonary hypertensioninthis retrospective cohort study.
Journalof Perinatology advanceonline publication, 19October 2017; doi:10.1038/jp.2017.166
INTRODUCTION vasoconstrictiveresponsetohypoxiathancontrols.7PHhasbeen
Pulmonaryhypertension(PH)isan increasinglyrecognizedcause showntobeanindependentriskfactorformortalityinBPDeven
of morbidity and mortality in premature infants.1–5 Both hypoxia when controlling for BPD disease severity.1,4,5 We, therefore,
and hyperoxia have been implicated as potential contributors to hypothesized that increased SpO 2 targets would lead to a
PHpathogenesisininfancy.6–12Optimaloxygensaturation(SpO ) reductioninPH invery low birthweight premature infants.
2
To investigate this hypothesis, we studied the rate of PH
toreducetheriskfordevelopingPHinprematureinfantshasnot
beenidentified. diagnosis in a large population of at risk premature infants
exposed to different SpO target ranges. On the basis of the
Indeed,thelargerquestionofoptimaloxygenSpO forpremature 2
2 results of several large oxygen saturation targeting trials, the
infants more generally remains an area of active inquiry and
debate.13–16 Concern forthe potentialof worsening retinopathy of neonatal intensive care unit (NICU) at Northside Hospital in
Atlanta, Georgia, a large, community-based level III NICU, has
prematurity (ROP) from excessive oxygen exposure has led to
reduced SpO targets;17–19 however other research suggests SpO twiceincreaseditsSpO 2targetsoverthelast5years.Wesetoutto
2 2 investigatewhetherratesofPHdiagnosisandPHmedicationuse
targetmaynotsignificantlyimpactdevelopment20orprogressionof
changedwithincreasing SpO targets.
ROP.21 In addition to the controversy over ROP, other morbidities 2
such as patent ductus arteriosus (PDA)22 and necrotizing enter-
ocolitis (NEC)14 may also be affected by SpO 2 targets. Perhaps the METHODS
most important and definitive endpoint, mortality, appears to also
Thisisaretrospectivecohortstudycomparingthreesetsofpatientsfrom
beaffectedbySpO 2targetsand,whilenotallstudiesareconsistent, eras defined by the unit-wide SpO
2
targets. A total of 1340 premature
the weight of evidence suggests that higher SpO 2 targets are infantswithgestationalagebetween23and32weeks,inclusive,andbirth
associatedwithlowerriskofmortality.13,14,17,23 weighto1500gmadmittedtoNorthsideHospitalNICUinAtlantaGeorgia
One possible mechanism to explain the observed reduction in betweenMay12009andMay312015werestudied.Cohort1consistedof
mortality in babies with higher SpO targets is that they might 459patientsbornbetweenMay12009andApril302011.Theunit-wide
have lower rates of PH. Unfortunat2 ely, PH diagnosis was not SpO 2 target range during that time frame was 85–94%. Cohort 2 was
reportedinthelargesaturationtargetingtrials14,18,23andwasan comprised of 494 patients born between May 1 2011 and May 31 2013
withSpO targetrangeof88–94%.Cohort3included387patientsborn
exclusioncriterioninone.20Hypoxiaisaknowncontributortothe betweenJ2
une12013andMay312015withSpO targetrangeof90–95%.
developmentofPHviavariousmechanisms6,24–27andinfantswith
ThebedsideSpO
alarmlimitswereidenticaltot2
hetargetedSpO ranges
2 2
BPD have been shown to have a more robust pulmonary for the study duration, giving real-time feedback to bedside caregivers.
1DepartmentofPediatrics,EmoryUniversitySchoolofMedicine,Atlanta,GA,USA;2Children’sHealthcareofAtlanta,Atlanta,GA,USA;3NorthsideHospital,Atlanta,GA,USAand
4Mednax,Sunrise,FL,USA.Correspondence:DrUKanaan,Pediatrics,EmoryUniversitySibleyHeartCenterCardiology,TheMcGillBuilding,Suite4002835BrandywineRd,Atlanta
30341,GA,USA.
E-mail:kanaanu@kidsheart.com
Received27February2017;revised11September2017;accepted12September2017
Saturationtargetandpulmonaryhypertension
UKanaanetal
2
Table1. Patientcharacteristics
Cohort1,N=459 Cohort2,N=494 Cohort3,N=387 P-valuea
Prenatalcharacteristics
Maternalpregnancyinducedhypertension 145(31.6%) 146(29.6%) 128(33.1%) 0.526
Maternalchorioamnionitis 20(4.4%) 47(9.5%) 39(10.1%) 0.002
Prenatalsteroids 392(85.4%) 442(89.5%) 351(90.7%) 0.037
Multiplegestation 150(32.7%) 152(30.8%) 111(28.7%) 0.455
Neonatalcharacteristics
Gestationalageatbirth,weeks 28(26–30) 28(26–30) 28(26–30) 0.767
Smallforgestationalage 111(24.2%) 108(21.9%) 83(21.4%) 0.578
Birthweight,grams 1000(765–1258) 1023(782–1268) 1044(775–1290) 0.265
MotherofHispanicorigin 45(9.8%) 43(8.7%) 49(12.7%) 0.147
Raceofmother
Black 180(39.2%) 217(43.9%) 167(43.2%) 0.007
White 207(45.1%) 195(39.5%) 139(35.9%)
Asian 14(3.1%) 31(6.3%) 32(8.3%)
Missingorunknown 58(12.6%) 51(10.3%) 49(12.7%)
Gender
Male 236(51.4%) 250(50.6%) 197(50.9%) 0.969
Female 223(48.6%) 244(49.4%) 190(49.1%)
Surfactantindeliveryroom 153(33.3%) 181(36.6%) 138(35.7%) 0.553
Apgarscoreat5min
o3 29(6.3%) 20(4.1%) 18(4.7%) 0.257
43 428(93.7%) 471(95.9%) 369(95.3%)
Respiratorycharacteristics
Oxygenondayoflife28 250(65.3%) 251(60.3%) 189(57.3%) 0.084
Oxygenat36weeksCGA 120(34.2%) 81(21.8%) 72(24.9%) o0.001
Useofinhalednitricoxide 29(6.5%) 15(3.1%) 10(2.6%) 0.007
SteroidsforCLD 46(10.2%) 109(22.3%) 79(20.7%) o0.001
Comorbiditycharacteristics
PDAligation 36(8.0%) 17(3.5%) 8(2.1%) o0.001
Necrotizingenterocolitis 40(8.9%) 20(4.1%) 9(2.4%) o0.001
PresenceofROPatdischarge
None/Mild(ostage2) 353(93.9%) 389(96.0%) 303(93.8%) 0.293
Severe(4stage2) 23(6.1%) 16(4.0%) 20(6.2%)
IVHgrade
None/Mild(o2) 392(91.2%) 428(92.2%) 335(92.5%) 0.747
Severe(42) 38(8.8%) 36(7.8%) 27(7.5%)
Invasiveinfectionafterdayoflife3 31(7.2%) 28(6.0%) 22(6.0%) 0.721
Abbreviations: CGA, corrected gestational age; CLD, chronic lung disease; IVH, intraventricular hemorrhage; PDA, patent ductus arteriosus; ROP, retinopathy of
prematurity.aOverallcomparisonacrossCohort1,2&3;categoricalvariablescomparedusingChi-squaretest;continuousvariablescomparedusingKruskal–Wallistest.
Also, as part of a quality assurance initiative, data from a computerized respiratory support. A consistent group of cardiologists interpreted
system tracking pulse oximetry ranges over longer stretches of time echocardiogramsduringthetimeframeofthestudyandallhadreceived
providedfeedbackstartingin2011. instruction from the PulmonaryHypertension Program Director (Kanaan)
Institutionalreviewboardapprovalwasobtainedfromallparticipating onstandardPHassessmentanddiagnosticcriteria.Criteriaforconsidera-
institutions: Northside Hospital, Pediatrix Medical Group and Children’s tion of a PH diagnosis were standardized (including elevated tricuspid
HealthcareofAtlanta.
regurgitantvelocity(43ms−1,436mmHg),elevatedpulmonaryinsuf-
ficiencyend-diastolicvelocity(41.5ms−1,49mmHg),righttoleftatrial
shunting, right to left ventricular shunting, right to left ductal shunting,
Clinicaldemographics
right ventricular dilation, right ventricular hypertrophy, right ventricular
Antenatal, birth and neonatal characteristics were obtained from the dysfunction); however clinical judgment to account for other factors
Vermont-Oxford Network database, as well as the clinical and adminis- impactingcardiovascularphysiologywasstressedleavingtheultimatePH
trative records maintained by neonatology group staffing the NICU diagnosisattreatingphysicians’discretion.Manysubjectshadmorethan
(Babysteps, Pediatrix Medical Group). An emphasis was placed on oneechocardiogramanddiagnosisofPHonanystudyledtoassignment
investigating parameters believed to be associated with PH diagnosis tothePHgroupforthepurposesofthisstudy(evenifPHhadnotbeen
such as small for gestational age (SGA, defined as birthweight o10th presentonpriorstudiesorresolvedinfollowup).ThediagnosisofPHwas
percentile for gestational age28), maternal chorioamnionitis and patent made by the treating neonatologist and pediatric cardiologist based on
ductusarteriosus(PDA). supportingimagingandclinicaldata,withtheneonatologistplacingthe
diagnosisinthemedicalrecord.UseofmedicationstotreatPHwasatthe
treating physicians’ discretion. Documentation of medication use was
Outcomes obtainedfromthemedicalrecordandconfirmedwiththeNICUpharmacy.
The standard practice in the Northside Hospital NICU is to perform PH-specific medication use, mortality, hospital length of stay, need for
monthlyechocardiogramstoassessforPHinprematureinfantsrequiring prolonged oxygen administration, presence of ROP, NEC and other
JournalofPerinatology(2017), 1–6 ©2017NatureAmerica,Inc.,partofSpringerNature.
Saturationtargetandpulmonaryhypertension
UKanaanetal
3
outcomespotentiallyaffectedbychangingoxygensaturationtargetswere Neonatalcharacteristicswerealsolargelysimilaracrosscohorts.
alsocomparedacrosscohorts. There were statistically significant trends in the racial makeup of
thecohortswithareductionintheWhitepopulationandincrease
Statistical analysis intheAsianpopulationovertime(P=0.007).Importantriskfactors
for PH and other morbidities in premature infants such as
StatisticalanalyseswereperformedusingSASversion9.4(Cary,NC,USA).
Statisticalsignificancewasassessedatthe0.05level.Descriptivestatistics gestational age at birth, small for gestational age status, birth
were calculated for all variables of interest and included medians and weight,surfactantdeliveryinthedeliveryroom,and5minApgar
interquartile ranges and counts and percentages, when appropriate. score didnot trendovertime.
CategoricalvariableswerecomparedacrossthethreeerasusingtheChi-
square test. Normality of continuous variables was assessed using Respiratory characteristics and comorbidities
histograms, normal probability plots and through the Anderson–Darling
Use of oxygen at day of life 28 was not different across cohorts,
testfornormality.Thedistributionofcontinuousvariableswascompared
acrossthethreeerasusingKruskal–Wallistests. however, oxygen use at 36 weeks corrected gestational age
Sincethereweredifferencesfoundbetweenthethreeeras(Table1),an decreasedovertimedespitethemorestringentSpO 2requirement
adjusted analysis was performed to control for these differences and (CGA; Cohort 1: 120 out of 459, 34.2%; Cohort 2: 81 out of 494,
potentialconfounders.Thisadjustedmodelincludedallvariablesthatwere 21.8%; Cohort 3: 72 out of 387, 24.9%; Po0.001). Post-natal
foundtobedifferentacrossthethreeeras(Table1,Po0.20),aswellas steroidusetotreatchroniclungdiseaseofprematurityincreased
variables that were associated with developing pulmonary hypertension overtime(Cohort1:46outof459,10.2%;Cohort2:109outof494,
(Table3, Po0.20)or thoughttobeclinicallyrelevantand hadsufficient 22.3%;Cohort 3: 79out of 387,20.7%;Po0.001).
sample size (missing o10% observations). In instances of collinearity, RatesofPDAligationdecreasedsignificantlyovertime(Cohort
collinearvariableswereexcluded.Forexample,inthecaseofbirthweight, 1:36outof459,8%;Cohort2:17outof494,3.5%;Cohort3:8out
smallforgestationalagestatusandgestationalage,onlygestationalage of 387, 2.1%; Po0.001) though information on the size or
andSGAwereincludedasthebirthweightisafunctionoftheothertwo significance of PDAs not referred for surgical ligation was not
variables.VariablesthatwerethoughttobecausedbyPHorpartofthePH
reviewed.NECratesalsodecreasedsignificantlyovertime(Cohort
treatment(forexample,oxygenondayoflife28,oxygenat36weekscGA,
1:40outof459,8.9%;Cohort2:20outof494,4.1%;Cohort 3:9
useofinhaltednitricoxideandsoon)werenotincludedintheadjusted
analysis. Variables included in the adjusted model were maternal
outof387,2.4%;Po0.001).ROP,IVHandinvasiveinfectionafter
pregnancyinducedhypertension,multiplegestation,smallforgestational dayof lifethreedid not trendovertime.
age, gestational age at birth, surfactant in delivery room, 5-min Apgar
score,IVHgradeandinvasiveinfectionafterdayoflife3.Variableswere Pulmonaryhypertensionand other outcomes
retainedintheadjustedanalysisregardlessofsignificancetoestimatethe
Table 2 summarizes the measured outcomes. The primary
effectofcohortinthepresenceofthesepotentialconfounders.
outcome, PH diagnosis, was significantly lower in the higher
To identify risk factors associated with in-hospital mortality, a multi-
variable logistic model was constructed. Univariable and multivariable SpO 2targetcohorts(Cohort1:87outof459,19.0%;Cohort2:39
logisticregressionwereusedtoobtainestimatesofassociationbetween out of 494, 7.9%; Cohort 3: 37 out of 387, 9.6%; Po0.001).
in-hospital mortality and each candidate predictor. Predictors that were Although cohort three had a slightly higher rate of PH diagnosis
significantly associated with in-hospital mortality at the univariable level comparedwithcohorttwo(9.6vs7.9%,P=0.382),thesewerenot
(Po0.20)andhadsufficientsamplesize(missing o10%ofobservations), statistically different whereas the overall trend for decreased PH
or were felt to be clinically relevant, were included in multivariable diagnosis with increasing saturations was significant (Po0.001).
modeling.Variablesremainedinthefinalmodeliftheyweresignificantat
Inhalednitricoxideusealsodecreasedwithincreasingsaturation
Po0.05. Odds ratios (OR) and 95% confidence intervals (CI) were target ranges (Cohort 1: 25 out of 459, 2.2%; Cohort 2: 14 out of
constructedforbothunivariableandmultivariablemodels.
494, 2.8%; Cohort 3: 9 out of 387, 2.3%; P=0.013). Other PH
medications were used infrequently and did not trend with
RESULTS increasingsaturationtargetranges.Inhospitalmortality,weightat
initialdisposition(dischargeortransfer),andinitiallengthofstay
Baselinedata (to firsttransfer ordischarge) did nottrendover time.
Table 1 summarizes patient characteristics between the three We compared characteristics and outcomes of infants with PH
cohorts.Prenatalcharacteristicsweresimilarwithrespecttorates withthosewhodidnotdevelopPHgroupingallcohortstogether
of multiparity and pregnancy induced hypertension, however, (Table3)andwithincohorts(notshown,notsignificantlydifferent
maternal chorioamnionitis rates (Cohort 1: 20 out of 459, 4.4%; from grouped data). This table was used to identify potential
Cohort 2: 47 out of 494, 9.5%; Cohort 3: 39 out of 387, 10.1%; confounding variables to include in our multivariable analysis
P=0.002) and prenatal steroid use (Cohort 1: 392 out of 459, (Table 4). Consistent with published studies of risk factors for
85.4%;Cohort2:442outof494,89.5%;Cohort3:351outof387, development of PH in premature infants, we found younger
90.7%;P=0.037)both increasedover time. gestational age at birth (26 weeks vs 28 weeks, Po0.001), SGA
Table2. Outcomes
Cohort1,N=459 Cohort2,N=494 Cohort3,N=387 P-valuea
Pulmonaryhypertension 87(19.0%) 39(7.9%) 37(9.6%) o0.001
In-hospitalmortality 73(15.9%) 66(13.4%) 47(12.1%) 0.265
Weightatinitialdisposition(g) 2468(1770–2985) 2448(2003–2910) 2440(2018–2840) 0.886
Initiallengthofstay(days) 53(30–77) 53(36–77) 53(36–74) 0.777
Inhalednitricoxideuse 25(5.4%) 14(2.8%) 9(2.3%) 0.028
Sildenafiluse 10(2.2%) 5(1.0%) 5(1.3%) 0.309
Bosentanuse 2(0.4%) 1(0.2%) 1(0.3%) 0.465
aOverallcomparisonacrossCohort1,2&3;categoricalvariablescomparedusingChi-squaretest;continuousvariablescomparedusingKruskal–Wallistest.
ValuesarepresentedasN(%)orMedian(25th–75th).
©2017NatureAmerica,Inc.,partofSpringerNature. JournalofPerinatology(2017), 1–6
Saturationtargetandpulmonaryhypertension
UKanaanetal
4
Table3. PHvsNoPH(N=1340) Table4. Unadjustedandadjustedeffectofcohortondiagnosisof
pulmonaryhypertension
PH,N=163 NoPH, P-value
(12.2%) N=1177 Unadjusted Adjusteda
(87.8%)
Prenataldata Oddsratio P-value Oddsratio P-value
Pregnancy-induced 43(26.4%) 376(31.9%) 0.151 (95%CI) (95%CI)
hypertension
Cohort
Maternal 19(11.7%) 87(7.4%) 0.059
Cohort1 Ref. – Ref. –
chorioamnionitis
Cohort2 0.37(0.24–0.54) o0.001 0.17(0.10–0.30) o0.001
Prenatalsteroids 141(86.5%) 1044(88.7%) 0.411
Cohort3 0.45(0.24–0.54) o0.001 0.24(0.13–0.42) o0.001
Multiplegestation 43(26.4%) 370(31.4%) 0.190
Motherofhispanicorigin 10(6.1%) 127(10.8%) 0.066 Abbreviation:CI=confidenceinterval.aAdjustedforallvariablesthatwere
significantly associated with developing pulmonary hypertension at the
Raceofmother univariatelevel(Po0.20inTable3)andhadsufficientsamplesize(missing
Black 68(41.7%) 496(42.1%) 0.221 o10% of observations), or were felt to be clinically relevant. Variables
White 71(43.6%) 470(39.9%) adjusted for were maternal pregnancy induced hypertension, maternal
Asian 12(7.4%) 65(5.5%) chorioamnionitis, prenatal steroids, multiple gestation, small for gesta-
Missingorunknown 12(7.4%) 146(12.4%) tionalage,gestationalageatbirth,motherofHispanic,race,surfactantin
deliveryroom,Apgarscoreat5min o3,steroidsforCLD,PDAligation,
Neonataldata necrotizingenterocolitis,IVHgrade⩾2andinvasiveinfectionafterdayof
Gestationalageatbirth 26(24–27) 28(26–30) o0.001 life3.Unadjustedandadjustedeffectofcohort(thatis,SpO saturation
Smallforgestationalage 55(33.7%) 247(21.0%) o0.001 targetrange)ondiagnosisofpulmonaryhypertension. 2
Birthweight 705(280– 1058(821– o0.001
917) 1283)
Male 83(50.9%) 600(51.0%) 0.989 surfactantinthedeliveryroom(66.3vs30.9%,Po0.001)orhave
Surfactantindelivery 108(66.3%) 364(30.9%) o0.001 hada5-minApgarscoreso3(8.6vs4.5%,P=0.026).Infantswith
room
Apgarscoreo3at5min 14(8.6%) 53(4.5%) 0.026 PH were more likely to require oxygen on day of life 28 (93.7 vs
57%, Po0.001), at 36 weeks CGA (78.2 vs 20.2%, Po0.001), or
Respiratorydata
receiveinhalednitricoxide(31.9vs0.2%,Po0.001)orsteroidsfor
Oxygenondayoflife28 118(93.7%) 572(57.0%) o0.001 chroniclungdisease(51.5vs13.0%,Po0.001).PDAligation(14.7
Oxygenat36weeksCGA 93(78.2%) 180(20.2%) o0.001 vs3.2%,Po0.001),severeROP(24.2vs3%,Po0.001),severeIVH
Useofinhalednitric 52(31.9%) 2(0.2%) o0.001 (23.3 vs 6%, Po0.001), and invasive infection after day of life 3
oxide (19.2 vs 4.7%, Po0.001) were all associated with PH diagnosis
SteroidsforCLD 84(51.5%) 150(13.0%) o0.001
whileNECwasnotassociatedwithPHinourdataset.In-hospital
Comorbiditydata mortalitywasalmostthree-foldhigherininfantswithPH(33.1vs
PDAligation 24(14.7%) 37(3.2%) o0.001 11.2%, Po0.001) in univariate modeling and this association
Necrotizingenterocolitis 9(5.5%) 60(5.2%) 0.859 between PH diagnosis and mortality remained on multivariable
testingwhilecontrollingforpotentialconfounders(OR=3.36;95%
PresenceofROPatdischarge CI: (2.04–5.55), Po0.001). Unsurprisingly, PH-specific medication
None/Mild(ostage2) 91(75.8%) 954(97.0%) o0.001
use was almost exclusively in the PH population. Hospital length
Severe(4stage2) 29(24.2%) 30(3.0%)
ofstayandweightatinitialdisposition(dischargeortransfer)were
IVHgrade notdifferent betweenPH and no PH groups.
None/Mild(ostage2) 115(76.7%) 1040(94.0%) o0.001 Ourprimaryoutcome,oddsofdevelopingPHbasedoncohort,
Severe(4stage2) 35(23.3%) 66(6.0%) is shown in Table 4 in both unadjusted and adjusted models. In
Invasiveinfectionafter 29(19.2%) 52(4.7%) o0.001 the unadjusted model, the odds ratio (OR) for developing PH in
day3 Cohort2was0.37(95%CI:(0.25–0.55),Po0.001)andinCohort3
was 0.45 (95% CI: (0.30–0.68), Po0.001) using Cohort 1 as the
Ou It nc -o hm oe spd ita at la
mortality 54(33.1%) 132(11.2%) o0.001
reference,demonstratingasignificantlyloweroddsofdeveloping
Weightatinitial 2010(1010– 2455(2044– 0.172 PHinthelatercohorts.Theeffectofcontrollingforvariablesthat
disposition 3325) 2895) were different among cohorts, different between PH and no PH
Initiallengthofstay 53(15–105) 53(36–74) 0.432 groups,andthosethatwerethoughttobeclinicallyrelevant,was
Inhalednitricoxideuse 47(28.8%) 1(0.1%) o0.001 tostrengthen therelationship betweencohort andPHdiagnosis.
Sildenafiluse 20(12.3%) 0(0.0%) o0.001 Variables adjusted for were maternal pregnancy induced hyper-
Bosentanuse 4(2.5%) 0(0.0%) o0.001
tension, maternal chorioamnionitis, prenatal steroid use, multiple
Abbreviations:CGA,correctedgestationalage;CLD,chroniclungdisease; gestation,smallforgestationalagestatus,gestationalageatbirth,
GI, gastrointestinal; IVH, intraventricular hemorrhage; NEC, necrotizing mother of Hispanic origin, maternal race, surfactant in delivery
enterocolitis; PDA, patent ductus arteriosus (treatment/closure includes room, 5-minute Apgar score o3, steroids for CLD, PDA ligation,
ibuprofen, indomethacin, surgical ligation and transcatheter device necrotizingenterocolitis,IVHgrade⩾2andinvasiveinfectionafter
closure); ROP, retinopathy of prematurity. Pooled characteristics and day of life 3. The odds of developing PH in Cohort 2 was 0.17
outcomes of all three cohorts dichotomized by PH diagnosis or no PH (0.10–0.30, Po0.001) and in Cohort 3 was 0.24 (0.13–0.42,
diagnosis using Chi-square test for categorical variables and Wilcoxon
Po0.001), whencontrolling forthese variables.
rank-sumtestforcontinuousvariables.
status(33.7vs21%,Po0.001),andlowerbirthweight(705gmvs DISCUSSION
1058gm, Po0.001) to be more common in infants diagnosed To our knowledge, this is the first publication investigating the
with PH in comparison with their non-PH counterparts. We also effect of changes in SpO targeting on the incidence of PH in
2
found that infants with PH were more likely to have received premature infants. In our large, community-based, tertiary NICU,
JournalofPerinatology(2017), 1–6 ©2017NatureAmerica,Inc.,partofSpringerNature.
Saturationtargetandpulmonaryhypertension
UKanaanetal
5
we found that incidence of PH decreased in association with ratesofmoresevereROPinourstudypopulation,likelyrelatedto
increased SpO target range. Our findings on PH incidence are shared risk factors though we cannot exclude a causal
2
congruent with the observed improvement in mortality with relationship.
higher SpO targets described in large SpO targeting trials.18,23 This retrospective cohort study is strengthened by the large
2 2
Thefindingssupportthepossibilitythatthereducedmortalityin numberofincludedpatientswith1340severelyprematureinfants
these studies (excluding the Canadian Oxygen Trial20 as PH caredforinasinglecenter.Aconsistentgroupofneonatologists
patients were excluded at time of enrollment) may be related to andpediatriccardiologistscaredforthesepatientsoverthistime
reductioninincidence ofPH. periodwhichservestolessenvariabilityindiagnosticcriteriaand
In-hospital mortality was not statistically different across our clinicalcareandhelpisolatetheimpactoftheSpO targetrange.
2
three cohorts. As with other published reports, though, PH Whileourpopulationisdrawnfromasinglecenter,itissimilarto
diagnosis was a significant independent risk factor for mortality previouslypublishedserieswithrespecttoriskfactorsforPHand
in our population increasing the odds of death by over 3-fold in outcomes.We,therefore,feelitisarepresentativegroupandour
our multivariable model.1,4,5 Gestational age at birth and SGA findingsare likely tobe generalizableto othercenters.
status have repeatedly been shown to be strong predictors of Asignificantlimitationofthisresearchistheabsenceofastrict
developing PH and we also found that in our analysis (data not diagnostic criterion for PH. Cardiac catheterization, the gold
shown).29Itisworthspecialmentionthatourcohortsdidnotvary standardforPHdiagnosis,isnotperformedininfantsatNorthside
withrespect tothese importantrisk factors. Hospitalandwasonlyperformedinasmallsubsetofthepatients
Other factors that may impact PH incidence were also largely after transfer to Children’s Healthcare of Atlanta. Echocardiogra-
similar across the three cohorts, though there were three phy,whilenotthegoldstandard,isthemodalitymostfrequently
differences that warrant discussion. We found increased use of used for PH diagnosis in this patient population. The interpreta-
prenatal steroids and increased maternal chorioamnionitis over tions of echocardiography in this population is challenging and
time, however, on multivariable analysis, neither of these factors multiple factors must be considered (post-natal age, systemic
was associated with PH diagnosis. In addition, there was no blood pressure, cardiac function, presence, magnitude and
difference in prenatal steroid use or chorioamnionitis diagnosis directionofshunts,anatomicvariablessuchasbranchpulmonary
between those with PH and those without PH. We extensively stenosisandsoon)makingtheuseofasingleparametertorulein
sought out an explanation for our finding of increased chor- or rule out PH impossible. We therefore chose to rely on the
ioamnionitis rates across cohorts through investigations with clinicaljudgmentofthetreatingphysiciansatthetimeofclinical
obstetrics, perinatology, and pathology departments at our assessmentasthemostlikelytobeaccurategaugeofwhetherPH
hospital and could not identify an explanation. There was no waspresentornot.Werecognizethattherewasalmostcertainly
change in definition, no increase in placental specimens somemisallocationofpatients;howeveranyerrorsarelikelytobe
submitted to pathology for review, and no identifiable change evenly distributed across cohorts. We did not have the ability to
in practice. It is worthy of note that chorioamnionitis rates retrospectively review echocardiograms from all eras as those in
increasedwhilePHdiagnosesfellsothelikelihoodofinterplayfor the earlier era are no longer available. A similar study designed
that variable is low. Post-natal steroid use did, however, go up prospectively allowingfor strictadherenceto aresearchimaging
over time and could be protective. It could, also, be part of a protocolandblindedreviewoftheimagesandclinicaldatawould
treatmentstrategy.Becausewedidnotknowthetimingofsteroid bean appropriate next stepto avoidthis pitfall.
use with respect to PH diagnosis, we included it in our model of Wearelimited,mostimportantly,bytheretrospectivenatureof
potentialconfoundersand,whenadjustedfor,didnotweakenthe this research, as well as the separation of the three cohorts over
linkbetween cohort and PH diagnosis. time.Otheraspectsofneonatalcarethatchangedoverthe6years
Unexpectedly,wefoundthatoxygenuseat36weeksCGAwas underreviewmayhaveimpactedPHdiagnosisrates.Queryingthe
lower in the higher SpO target range cohorts in contrast to the physiciansinvolvedoverthoseyearshelpedtoidentifychangesin
2
SUPPORT trial.18 One possible explanation for this finding is that unit policies or practice. Those that may have had an impact on
reduction in intermittent hypoxic episodes in the higher satura- these results include use of donor breastmilk, less aggressive
tion groups may have a positive effect on lung health.6 Another medical and surgical treatment of PDA, increased feedback to
contributorcouldbegreatereffortsaimedatadherencetooxygen bedside nurses regarding time babies spent within intended
saturation targets in our NICU from 2012 onward in response to saturation ranges, and increasing use of non-invasive ventilation.
emergingawareness oftheimportance ofSpO targeting. Wemustrecognizethattheseandotherchangesinneonatology
2
The use of PDA ligation decreased significantly over time. This practicemayhaveledtotheobservedreductionofPHdiagnosis,
may reflect a reduction in the incidence of hemodynamically notthechangeinSpO targetrange.Aprospective,randomized,
2
significant PDA due to increased oxygen saturations—a finding blindedstudywouldberequiredtoisolateSpO targetrangefrom
2
suggested by Inomata et al. and consistent with oxygen’s role in other potential confounders. In the absence of a new trial, the
inducingductalclosure.22,30This,inturn,mightleadtoareduction charts and imaging tests of the infants included in the large
inshearstressonthepulmonaryarterialendotheliumandresultin saturation targeting trials could be reviewed to confirm or refute
lower rates of PH. Another explanation that must be considered, our finding.
though, is that clinical practice inthis NICU has fallen away from We also recognize that subjects born near the end of the
ductal ligation in most cases. We must, therefore, consider the timeframe of their cohort will largely be exposed to the oxygen
possibilitythatareductioninPDAligationledtoareductioninPH, saturation target range of the subsequent cohort. As we do not
nottheincreaseinSpO targetrange.However,whencontrolling knowwhatthecriticaltimeframeforsaturationtargetexposureis,
2
for PDA ligation (among other potential confounders) on multi- weoptedaprioritoincludesubjectsbasedonthepolicyinplace
variabletesting,theoddsofdevelopingPHwentdowncompared on the date of birth. However, to determine if the results would
to the unadjusted model so it does not appear that reduction in havebeenchangedbysplittingthecohortsdifferently,were-ran
PDAligationledto thereductioninPH diagnosis. the analysis using cohort assignment based on discharge date
Incontrast to theexperience of Manleyet al.19 we experience, (data not shown) and found no significant difference in the
wedidnotfindanysignificantchangeintherateofROPdiagnosis outcomes.Wealsoconsideredwhethertimespentoutsideofthe
orseveritywithincreasedSpO targetrange.Thisisanimportant NICU at Northside Hospital could have introduced another
2
findingasconcernrelatedtoriskofoxygenonROPdevelopment confounder. We, therefore, performed a separate sub-analysis
is one of the most often cited rationales for maintaining lower (data not shown) excluding infants who spent any time at other
saturation targets. Interestingly, PH was associated with higher institutionswhomayhavebeenexposedtodifferentSpO targets
2
©2017NatureAmerica,Inc.,partofSpringerNature. JournalofPerinatology(2017), 1–6
Saturationtargetandpulmonaryhypertension
UKanaanetal
6
(n=35 born at other institutions who were transferred into 10 LakshminrusimhaS,RussellJA,SteinhornRH,RyanRM,GuginoSF,MorinFC3rd
Northside Hospital after birth, n=200 transferred out transiently et al. Pulmonary arterial contractility in neonatal lambs increases with 100%
orpermanentlytootherinstitutionsmainlyforsurgicalprocedures, oxygenresuscitation.PediatrRes2006;59:137–141.
andn=9thatmetbothofthesecriteria).Thissub-analysisresulted 11 Lakshminrusimha S,Russell JA,Steinhorn RH, SwartzDD, RyanRM,GuginoSF
innomeaningfulchangeinanyoftherelevantoutcomemeasures. etal.Pulmonaryhemodynamicsinneonatallambsresuscitatedwith21%,50%,
and100%oxygen.PediatrRes2007;62:313–318.
12 Wedgwood S, Steinhorn RH. Role of reactive oxygen species in neonatal pul-
CONCLUSION monaryvasculardisease.AntioxidRedoxSignal2014;21:1926–1942.
13 ManjaV,SaugstadOD,LakshminrusimhaS.Oxygensaturationtargetsinpreterm
In our large, retrospective, single-center experience, exposure to infantsandoutcomesat18–24months:asystematicreview.Pediatrics2017;139:
higherSpO 2 target ranges was associated with lowerrates of PH e20161609.
diagnosis. Reduction in mortality with higher saturation targets 14 Manja V, Lakshminrusimha S, Cook DJ. Oxygen saturation target range for
observed in other large saturation targeting studies may be extremelypreterminfants:asystematicreviewandmeta-analysis.JAMAPediatr
related to reduction in the incidence of PH. Further prospective 2015;169:332–340.
researchtoconfirmthis finding is warranted. 15 PolinR,BatemanD.Oxygen-saturationtargetsinpreterminfants.NEnglJMed
2013;368:22.
16 CummingsJJ,PolinRA,AAPCommitteeonFetusandNewborn.Oxygentargeting
CONFLICTOFINTEREST inextremelylowbirthweightinfants.Pediatrics2016;138:e20161576.
17 Chow LC, Wright KW, Sola A, CSMC Oxygen Administration Study Group. Can
DrKanaanandMsHuckabyreceiveresearchsupportbutnopersonalremuneration
changes in clinical practice decrease the incidence of severe retinopathy of
from Eli Lilly and Company and from the Association for Pediatric Pulmonary prematurityinverylowbirthweightinfants?.Pediatrics2003;111:339–345.
Hypertension (a non-profit research organization supported by Actelion
18 CarloW,FinerN,WalshM,RichW,GantzM,LaptookAetal.SUPPORTStudy
Pharmaceuticals,Ltd.).Theremainingauthorsdeclarenoconflictofinterest.
GroupoftheEuniceKennedyShriverNICHDNeonatalResearchNetwork.Target
rangesofoxygensaturationinextremelypreterminfants.NEnglJMed2010;363:
ACKNOWLEDGEMENTS
1959–1969.
19 ManleyBJ,KuschelCA,ElderJE,DoyleLW,DavisPG.Higherratesofretinopathy
We appreciate and benefitted from the help and support of Dr Reese Clark, the ofprematurityafterincreasingoxygensaturationtargetsforverypreterminfants:
researchdepartmentatMednax,andCourtneyMcCracken,PhD. experienceinasinglecenter.JPediatr2016;168:242–244.
20 Schmidt B, Whyte RK, Shah PS, Abbasi S, Bairam A, Harrold J et al. Canadian
OxygenTrial(COT)Group.Effectsoftargetinghigherorloweroxygensaturations
REFERENCES
incenterswithmoreversuslessseparationbetweenmediansaturations.JPediatr
1 Khemani E, McElhinney DB, Rhein L, Andrade O, Lacro RV, Thomas KC et al.
2016;178:288–291.
Pulmonary artery hypertension in formerly premature infants with broncho- 21 STOP-ROPMulticenterStudyGroup.Supplementaltherapeuticoxygenforpre-
pulmonary dysplasia: clinical features and outcomes in the surfactant era. thresholdretinopathyofprematurity(STOP-ROP),arandomized,controlledtrial.I:
Pediatrics2007;120:1260–1269. primaryoutcomes.Pediatrics2000;105:295–310.
2 MirzaH,ZieglerJ,FordS,PadburyJ,TuckerR,LaptookA.Pulmonaryhypertension 22 InomataK,TaniguchiS,YonemotoH,InoueT,KawaseA,KondoY.Lowerearly
inpreterminfants:prevalenceandassociationwithbronchopulmonarydysplasia. postnataloxygensaturationtargetandriskofductusarteriosusclosurefailure.
JPediatr2014;165:909–914. PediatrInt2016;58:1153–1157.
3 BhatR,SalasA,FosterC,CarloW,AmbalavananN.Prospectiveanalysisofpul- 23 Tarnow-MordiW,StensonB,KirbyA,JuszczakE,DonoghoeM,DeshpandeSetal.
monaryhypertensioninextremelylowbirthweightinfants.Pediatrics2012;129: BOOST-IIAustraliaandUnitedKingdomCollaborativeGroups.Outcomesoftwo
e682–e689. trialsofoxygen-saturationtargetsinpreterminfants. NEnglJMed2016;374:
4 Slaughter JL, Pakrashi T, Jones DE, South AP, Shah TA. Echocardiographic 749–760.
detectionofpulmonaryhypertensioninextremelylowbirthweightinfantswith 24 Sylvester JT, Shimoda LA, Aaronson PI, Ward JP. Hypoxic pulmonary vasocon-
bronchopulmonarydysplasiarequiringprolongedpositive pressureventilation. striction.PhysiolRev2012;92:367–520.
JPerinatol2011;10:635–640. 25 Dunham-Snary KJ, Wu D, Sykes EA, Thakrar A, Parlow LR, Mewburn JD et al.
5 Berenz A, Vergales JE, Swanson JR, Sinkin RA. Evidence of early pulmonary Hypoxicpulmonaryvasoconstriction:frommolecularmechanismstomedicine.
hypertension is associated with increased mortality in very low birthweight Chest2017;151:181–192.
infants.AmJPerinatol2017;34(8):801–807. 26 SemenzaGL.Oxygensensing,hypoxia-induciblefactors,anddiseasepathophy-
6 Martin RJ, Di Fiore JM, Walsh MC. Hypoxic episodes in bronchopulmonary siology.AnnuRevPathol2014;9:47–71.
dysplasia.ClinPerinatol2015;42:825–838. 27 Kylhammar D, Rådegran G. The principal pathways involved in the in vivo
7 MouraniPM,IvyDD,GaoD,AbmanSH.Pulmonaryvasculareffectsofinhaled modulation of hypoxic pulmonary vasoconstriction, pulmonary arterial remo-
nitricoxideandoxygentensioninbronchopulmonarydysplasia.AmJRespirCrit delingandpulmonaryhypertension.ActaPhysiol2017;219:728–756.
CareMed2004;170:1006–1013. 28 OlsenIE,GrovemanMS,LawsonML,ClarkRH,ZemelBS.Newintrauterinegrowth
8 GittoE,PellegrinoS,AversaS,RomeoC,TrimarchiG,BarberiIetal.Oxidative curvesbasedonUnitedStatesData.Pediatrics2010;125:e214–e224.
stress and persistent pulmonary hypertension of the newborn treated with 29 NaguibM,KanaanU,SimonD,GuglaniL.Riskfactorsfordevelopmentofpul-
inhalednitricoxideanddifferentoxygenconcentrations.JMaternFetalNeonatal monary hypertension in infants with bronchopulmonary dysplasia:systematic
Med2012;25:1723–1726. reviewandmeta-analysis.PaediatrRespirRev.23:27–32.
9 Lakshminrusimha S, Swartz DD, Gugino SF, Ma CX, Wynn KA, Ryan RM et al. 30 RudolphAM.Theductusarteriosusandpersistentpatencyoftheductusarter-
Oxygen concentration and pulmonary hemodynamics in newborn lambs with iosus.CongenitalDiseasesoftheHeart:Clinical-PhysiologicalConsiderations.Future
pulmonaryhypertension.PediatrRes2009;66:539–544. PublishingCompany,Inc.:NewYork,2001,pp155–196.
JournalofPerinatology(2017), 1–6 ©2017NatureAmerica,Inc.,partofSpringerNature.
